Egetis Sells Priority Review Voucher for $190M After First MCT8 Deficiency Drug
· techtimes.com · popularity 17/100 · 0 similar stories today · Genetics, Genomics & Biotech (Science)
Read the original at techtimes.com →
Summary
Priority review voucher: Egetis Therapeutics sells its FDA certificate for $190 million after winning U.S. approval for Emcitate (tiratricol), the first treatment for MCT8 deficiency, a rare neurological disorder affecting 1 in 70,000 males, illustrating how rare-disease drug approvals generate transferable FDA fast-track certificates worth $180-220 million each in 2026.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 13.